Analysis and Evaluation of Ultrasound Imaging Features and Pathological Results of Ovarian Cancer

2021 ◽  
Vol 11 (3) ◽  
pp. 981-987
Author(s):  
Yuqing Zhang ◽  
Yan Li ◽  
Mei Wu ◽  
Feixue Zhang ◽  
Guangrui Shao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Early Diagnosis ◽  
Cancer Patients ◽  
Ultrasound Imaging ◽  
Malignant Tumors ◽  
Maximum Diameter ◽  
Pathological Examination ◽  
Imaging Features ◽  
Specificity And Sensitivity ◽  
Different Ages

To compare and analyze the relationship between the characteristics of ultrasound images of ovarian cancer and the results of postoperative pathological examination. A retrospective analysis of 206 patients with suspected ovarian cancer confirmed by surgical pathology was taken as the research object. The location, size, morphology, partition and wall nodules, cystic solidity, and signal characteristics of the tumor were observed and compared with the results of postoperative pathological examination evaluation and analysis to improve the early clinical diagnosis of ovarian cancer patients. By regression analysis of the histological examination of patients with ovarian tumors of different ages and the proportion of cox postoperative recurrence risk regression models, 154 of 206 ovarian tumor patients were ovarian cancer. There were significant differences in pathological types, lesion locations, maximum diameter lengths, and internal echo in patients with ovarian malignant tumors at different ages (p < 0.05). Ultrasound of ovarian cancer shows that the tumor has large tumor body, strong echo, cyst wall has protrusions, and peripheral and internal blood flow that is mainly high-speed and low-resistance. The sensitivity, specificity, and accuracy of ultrasound for ovarian cancer diagnosis are 84.38%, 66.67%, 81.01%. The accuracy, specificity, and sensitivity of early diagnosis of clinical ovarian cancer patients by ultrasound imaging features provide sufficient imaging evidence to further promote the clinical judgment of benign and malignant tumors, which is beneficial to doctors’ clinical treatment of ovarian cancer patients. The early diagnosis and the higher clinical value were shown.

scholarly journals The Mechanism and Clinical Significance of Circular RNAs in Hepatocellular Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Ziyue Huang ◽  
Haoming Xia ◽  
Shuqiang Liu ◽  
Xudong Zhao ◽  
Risheng He ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Early Diagnosis ◽  
Molecular Mechanisms ◽  
Immune Escape ◽  
Clinical Symptoms ◽  
Malignant Tumors ◽  
Research Progress ◽  
Circular Rnas ◽  
Transcriptional Level ◽  
Specificity And Sensitivity

Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors worldwide. In view of the lack of early obvious clinical symptoms and related early diagnostic biomarkers with high specificity and sensitivity, most HCC patients are already at the advanced stages at the time of diagnosis, and most of them are accompanied by distant metastasis. Furthermore, the unsatisfactory effect of the follow-up palliative care contributes to the poor overall survival of HCC patients. Therefore, it is urgent to identify effective early diagnosis and prognostic biomarkers and to explore novel therapeutic approaches to improve the prognosis of HCC patients. Circular RNA (CircRNA), a class of plentiful, stable, and highly conserved ncRNA subgroup with the covalent closed loop, is dysregulated in HCC. Increasingly, emerging evidence have confirmed that dysregulated circRNAs can regulate gene expression at the transcriptional or post-transcriptional level, mediating various malignant biological behaviors of HCC cells, including proliferation, invasion, metastasis, immune escape, stemness, and drug resistance, etc.; meanwhile, they are regarded as potential biomarkers for early diagnosis and prognostic evaluation of HCC. This article reviews the research progress of circRNAs in HCC, expounding the potential molecular mechanisms of dysregulated circRNAs in the carcinogenesis and development of HCC, and discusses those application prospects in the diagnosis and prognosis of HCC.

scholarly journals Improved prognosis for recurrent epithelial ovarian cancer by early diagnosis and 125I seeds implantation during suboptimal secondary cytoreductive surgery: a case report and literature review

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Lin Xiao ◽  
Junying Tang ◽  
Wenbo Li ◽  
Xuexun Xu ◽  
Hao Zhang
Keyword(s):  
Ovarian Cancer ◽  
Early Diagnosis ◽  
Epithelial Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Malignant Tumors ◽  
Recurrent Ovarian Cancer ◽  
R0 Resection ◽  
Iliac Vessel ◽  
Secondary Cytoreductive Surgery ◽  
125I Seeds

Abstract Background Epithelial ovarian cancer (EOC) has the worst prognosis in all of gynecologic malignant tumors because of its high recurrence and eventually chemo-resistance. Early diagnosis of recurrence is crucial to avoid diffuse dissemination. Failure of traditional treatment in recurrent epithelial ovarian cancer remains a challenge for clinicians. On the other hand, 125I brachytherapy has been accepted as a useful and hopeful treatment for multiple advanced cancers in recent years. However, its success in advanced epithelial ovarian cancer is limited. Here we report a case of recurrent ovarian cancer who had been early diagnosis of isolated recurrence and successfully treated with 125I seeds implantation during suboptimal cytoreductive surgery. Case presentation A 59-year-old woman presented with recurrent epithelial ovarian cancer who have had a history of ovarian cancer stage IIIB and an R0 resection had been achieved nearly 2 years before presented in our hospital. She underwent suboptimal secondary cytoreductive surgery after four cycles of chemotherapy with little effectiveness and severe chemotherapy-related side effects. Approximately 70% of the cancer-bulk was resected during surgery. For residual lesion which fixed around the right ureter and right external iliac vessel, 125I seeds implantation was performed. Postoperatively, the patient was treated with two cycles of combination chemotherapy with paclitaxel and carboplatin. The patient was free of disease at 26 months’ follow-up period. Conclusion In recurrent EOC patients with unresectable isolated lesion, salvage 125I seeds implantation are feasible and may contribute to survival.

Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy

2002 ◽  
Vol 12 (3) ◽  
pp. 250-256 ◽  
Author(s):  
K Fujiwara ◽  
S Suzuki ◽  
E Yoden ◽  
H Ishikawa ◽  
Y Imajo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Radiation Therapy ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Symptomatic Relief ◽  
Treatment Options ◽  
Median Number ◽  
Maximum Diameter ◽  
External Irradiation ◽  
Local Radiation

Abstract.Fujiwara K, Suzuki S, Yoden E, Ishikawa H, Imajo Y, Kohno I. Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.The purpose of this paper is to prospectively evaluate the effects of local radiation therapy upon localized ovarian cancer following chemotherapy. Patients with objective relapses or refractory disease but with localized epithelial ovarian cancers and who had undergone at least one regimen of chemotherapy were enrolled in this study. External irradiation was performed on all patients. Twenty patients, with a mean age of 53.8 ± 10.3 y, were enrolled in this study. The median number of previous chemotherapies was 2. The interval between previous chemotherapy and radiation therapy was 4.5 months. The maximum diameter of the lesions was 3.6 ± 1.8 cm. The irradiation dose was 52.3 ± 8.3 Gy. Neither hematologic nor intestinal toxicity >grade 3 was observed. Forty-four disease sites, including the lymph nodes, vaginal cuff, pelvis, abdomen, subcutaneous regions, and the brain were irradiated. Thirty of these sites were symptom-free before irradiation. In patients with symptoms, the symptomatic relief was obtained in approximately 50% of patients. Smaller lesions (P = 0.024) and lymph nodes (P = 0.042) demonstrated better responses than larger lesions or other sites, respectively. Regression rates correlated with longer survivals (P = 0.0195) after radiation therapy. Survival was significantly better when radiation therapy was given before patients had symptoms (P = 0.001). Survival was also better in patients with lymph node disease only (P = 0.0069). We conclude that local radiation therapy may be one of the treatment options for relapsed or refractory but localized ovarian cancer, particularly when the tumor is small and/or located in the lymph nodes, even when patients had no symptoms.

scholarly journals Improved Prognosis for Recurrent Epithelial Ovarian Cancer By early Diagnosis and 125I Seeds Implantation During Suboptimal Secondary Cytoreductive Surgery: A Case Report and Literature Review

2020 ◽  
Author(s):  
lin xiao ◽  
Junying Tang ◽  
Wenbo Li ◽  
Xuexun Xu ◽  
Hao Zhang
Keyword(s):  
Ovarian Cancer ◽  
Early Diagnosis ◽  
Epithelial Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Malignant Tumors ◽  
Recurrent Ovarian Cancer ◽  
R0 Resection ◽  
Iliac Vessel ◽  
Secondary Cytoreductive Surgery ◽  
125I Seeds

Abstract Background: Epithelial ovarian cancer (EOC) has the worst prognosis in all of gynecologic malignant tumors because of its high recurrence and eventually chemo-resistance. Early diagnosis of recurrence is crucial to avoid diffuse dissemination. Traditional treatment failure in recurrent ovarian cancer remains a challenge for clinicians. On the other hand, 125I brachytherapy has been accepted as a useful treatment for multiple advanced cancers in recent years. However, its success in advanced epithelial ovarian cancer is limited. Here we report a case of recurrent ovarian cancer who had been early diagnosis of isolated recurrence and successfully treated with 125I seeds implantation during suboptimal cytoreductive surgery.Case presentation: A 59-year-old woman presented with recurrent epithelial ovarian cancer who have had a medical history of ovarian cancer stage IIIB and an R0 resection had been achieved before presented in our hospital. She underwent suboptimal secondary cytoreductive surgery after four cycles of chemotherapy with little effectiveness and severe chemotherapy-related side effects. Approximately 70% of the cancer-bulk was resected during surgery. For residual lesion which fixed around the right ureter and right external iliac vessel, 125I seeds implantation was performed. Postoperatively, the patient was treated with two cycles of combination chemotherapy with paclitaxel and carboplatin. The patient was free of disease at 26 months’ follow-up period. Conclusion: In recurrent EOC patients with unresectable isolated lesion, salvage 125I seeds implantation are feasible and may contribute to survival.

scholarly journals Identification of KIF23 as a prognostic signature for ovarian cancer based on large scale samples and clinical validation

2020 ◽  
Author(s):  
Yuexin Hu ◽  
Mingjun Zheng ◽  
Caixia Wang ◽  
Shuang Wang ◽  
Rui Gou ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Large Scale ◽  
Cox Regression ◽  
Malignant Tumors ◽  
Chemotherapy Resistance ◽  
Survival Prognosis ◽  
Molecular Targeted Drug

Abstract Background: Ovarian cancer is one of the common malignant tumors in gynecology. Although the treatment strategy for ovarian cancer has been greatly improved in recent years, due to the metastasis, recurrence and drug resistance, the 5-year overall survival rate of patients is still less than 47%. However, at present, there is no specific markers for clinical application. The purpose of this study is to verify the expression and clinical significance of KIF23 in ovarian cancer and identify potential targets for the clinical treatment of ovarian cancer. Methods: The expression of KIF23 in ovarian cancer tissues and its relationship between survival prognosis and clinical pathological parameters were analyzed in Oncomine, GEO, and TCGA databases. KIF23 expression was analyzed by Kaplan-Meier plotter database and its relationship with chemo-resistance was studied. The molecular mechanism involved in KIF23 was analyzed from the perspective of gene mutation, copy number variation and other genomics. Finally, immunohistochemistry experiment was used to verify the expression of KIF2, and its relationship between the clinical pathological parameters and prognosis of ovarian cancer patients was analyzed by single factor and multivariate Cox regression models. Results: Bioinformatic and experimental results have demonstrated that KIF23 is highly expressed in ovarian cancer, and its high expression is positively correlated with poor prognosis. Overexpression of KIF23 can cause chemotherapy resistance in ovarian cancer and affect the overall survival of patients. Genomics analysis showed that KIF23 expression was associated with mutations such as FLG2 and TTN, and it was significantly enriched in tumor signaling pathways such as DNA replication and cell cycle. Conclusions: KIF23 can not only be used as a biomarker of poor prognosis in patients with various stages of ovarian cancer, but also be used as a molecular targeted drug and an independent prognostic biomarker for the treatment of ovarian cancer patients.

Eukaryotic Initiation Factor 5A2 (EIF5A2) Contributes to Ovarian Tumor Growth and Metastasis

2020 ◽  
Author(s):  
◽  
Guannan Zhao ◽  
Keyword(s):  
Ovarian Cancer ◽  
Mortality Rate ◽  
Early Diagnosis ◽  
Cancer Patients ◽  
Ovarian Tumor ◽  
Initiation Factor ◽  
Advanced Stage ◽  
Eukaryotic Initiation Factor ◽  
Ovarian Cancers ◽  
Tumor Growth And Metastasis

Ovarian cancer has the highest mortality rate among all gynecological malignancies due to lack of effective biomarkers for early diagnosis. The majority of ovarian cancer patients are already at an advanced stage when diagnosed. In addition, ovarian cancers often become chemoresistant and metastatic, and recur following initial chemotherapy.

scholarly journals Analysis of expression and prognosis of KLK7 in ovarian cancer

Open Medicine ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. 932-939
Author(s):  
Erhua Chen ◽  
Huifang Zhu ◽  
Yue Yang ◽  
Ling Wang ◽  
Jianhua Zhang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Malignant Tumors ◽  
Pearson Correlation ◽  
Cancer Cell Line ◽  
Progression Free Survival ◽  
Reproductive Organs ◽  
Clinical Prognosis ◽  
Cancer Data ◽  
The Impact

AbstractBackgroundOvarian cancer is one of the common malignant tumors in female reproductive organs. Kallikrein-related peptidase (KLK) 7 is a secreted serine peptidase that is related to different cancer. To investigate the expression and significance of KLK7 in ovarian cancer.Materials and methodsThe expression of KLK7 in human ovarian cancer was evaluated by Oncomine and Cancer Cell Line Encyclopedia database. Then the co-expression genes relevant to the KLK7 gene were analyzed by the Pearson correlation test. Finally, the impact of KLK7 on clinical prognosis was investigated in distinct subtypes of ovarian cancer patients by UALCAN database and Kaplan–Meier plotter database.ResultsIt was found that the expression of KLK7 was higher in ovarian cancer compared with other types of cancer, such as gastric cancer and pancreatic cancer. The expression of KLK7 was found to be increased in four various ovarian cancer data sets compared with the healthy tissues. In addition, upregulation of KLK7 expression was associated with age and cancer stage. Moreover, survival analysis revealed that higher KLK7 expression was negatively associated with progression-free survival.ConclusionKnowledge of the expression of KLK7 may be useful for better understanding the outcome in ovarian cancer patients.

scholarly journals Screening key genes related to ovarian cancer and exploring their possible molecular mechanisms

2019 ◽  
Author(s):  
Junzui Li ◽  
Yuehua Zhang ◽  
Zhixiong Huang ◽  
Bin Zhao ◽  
Ke Huang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Early Diagnosis ◽  
Candidate Genes ◽  
Molecular Mechanisms ◽  
Clinical Symptoms ◽  
Malignant Tumors ◽  
Enrichment Analysis ◽  
Pathway Enrichment Analysis ◽  
Hub Genes ◽  
Key Genes

Abstract Background As one of the common malignant tumors in women, ovarian cancer (OC) often exerts the atypically early clinical symptoms. Therefore, it is particularly important for seeking more effectively early diagnosis of OC (biomarkers). Besides, although a lot of sequencing and chip research have been done on the pathogenesis of OC, the pathogenesis, clinical and genetic features of OC is still not very clear.Methods In this study, 4 GEO data (GSE66957, GSE119054, GSE14407 and GSE54388) were selected for differential expression gene analysis (DEGs), and the important template of the 4 DEGS overlapping genes was taken as Hub genes. Then, the GO and pathway enrichment analysis were conducted to confirm the enrichment of these Hub genes, and these Hub genes were identified as key genes. In addition, the transcriptional levels of these Hub genes in OC and their impacts on the overall survival rate of OC were validated via the UCSC and TCGA datasets.. Besides, cBioPortal, TargetScan, UCSC, DiseaseMeth and TIMER software were performed to explore the potential biological functions of these key genes in OC.Results We screened out 10 Hub genes related to OC including VEGFA, ZWINT, CDKN2A, SLC2A1, TOP2A, MKI67, CCND1, KPNA2, FGF2 and SMC4, and further demonstrated that they were most significantly enriched in protein binding, cytoplasm, nucleus, extracellular exosome, membrane, cell division, cell adhesion and pathways in cancer. Meanwhile, CCND1, TOP2A, SMC4 and FGF2 were screened out as key candidate genes associated with OC. Further analysis proved these key candidate genes may regulate the occurrence and development of OC through mediating the gene mutation, miRNAs and genetic epigenetics such as methylation and acetylation.Conclusion These data would improve our understanding of the causes and underlying molecular events of OC, be of clinical significance for the early diagnosis and prevention of OC, and may provide the promising therapeutic targets in OC.

scholarly journals Improved prognosis for recurrent epithelial ovarian cancer by early diagnosis and 125I seeds implantation during suboptimal secondary cytoreductive surgery: a case report and literature review

2020 ◽  
Author(s):  
lin xiao ◽  
Junying Tang ◽  
Wenbo Li ◽  
Xuexun Xu ◽  
Hao Zhang
Keyword(s):  
Ovarian Cancer ◽  
Early Diagnosis ◽  
Epithelial Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Malignant Tumors ◽  
Recurrent Ovarian Cancer ◽  
R0 Resection ◽  
Iliac Vessel ◽  
Secondary Cytoreductive Surgery ◽  
125I Seeds

Abstract Background: Epithelial ovarian cancer (EOC) has the worst prognosis in all of gynecologic malignant tumors because of its high recurrence and eventually chemo-resistance. Early diagnosis of recurrence is crucial to avoid diffuse dissemination. Failure of traditional treatment in recurrent epithelial ovarian cancer remains a challenge for clinicians. On the other hand, 125I brachytherapy has been accepted as a useful and hopeful treatment for multiple advanced cancers in recent years. However, its success in advanced epithelial ovarian cancer is limited. Here we report a case of recurrent ovarian cancer who had been early diagnosis of isolated recurrence and successfully treated with 125I seeds implantation during suboptimal cytoreductive surgery.Case presentation: A 59-year-old woman presented with recurrent epithelial ovarian cancer who have had a history of ovarian cancer stage IIIB and an R0 resection had been achieved nearly two years before presented in our hospital. She underwent suboptimal secondary cytoreductive surgery after four cycles of chemotherapy with little effectiveness and severe chemotherapy-related side effects. Approximately 70% of the cancer-bulk was resected during surgery. For residual lesion which fixed around the right ureter and right external iliac vessel, 125I seeds implantation was performed. Postoperatively, the patient was treated with two cycles of combination chemotherapy with paclitaxel and carboplatin. The patient was free of disease at 26 months’ follow-up period. Conclusion: In recurrent EOC patients with unresectable isolated lesion, salvage 125I seeds implantation are feasible and may contribute to survival.

scholarly journals Exosomal microRNAs in hepatocellular carcinoma

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chenbin Liu ◽  
Han Wu ◽  
Yinqi Mao ◽  
Wei Chen ◽  
Shuying Chen
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Microenvironment ◽  
Early Diagnosis ◽  
Target Genes ◽  
Malignant Tumors ◽  
High Specificity ◽  
Early Screening ◽  
Active Mechanism ◽  
Specificity And Sensitivity ◽  
And Function

AbstractHepatocellular carcinoma is one of the most common malignant tumors worldwide and the fourth leading cause of cancer-related deaths. The prognosis of hepatocellular carcinoma patients is extremely poor due to the occult onset and high metastasis of hepatocellular carcinoma. Therefore, biomarkers with high specificity and sensitivity are of great importance in early screening, diagnosis prognosis, and treatment of hepatocellular carcinoma patients. Exosomes are tiny vesicles secreted by various types of cells, which can serve as mediators of intercellular communication to regulate the tumor microenvironment, and play a key role in the occurrence, development, prognosis, monitor and treatment of hepatocellular carcinoma. As microRNA deliverer, exosomes are involved in multiple life activities by regulating target genes of recipient cells such as proliferation, invasion, metastasis and apoptosis of cancer cells. In this review, we summarized the composition, active mechanism and function of exosomal microRNAs in hepatocellular carcinoma, and elaborated on their potential application value of early diagnosis and treatment in hepatocellular carcinoma.

Sign in / Sign up

Export Citation Format

Share Document